Xiangrong Shi — Nantong University

Area of research

Cardiology and Cardiovascular Medicine · Complementary and alternative medicine

Research interest

Research interests include Medicine, Gefitinib, Epidermal growth factor receptor, T790M, In vivo, and Cancer.

Recent publications

Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer in vitro and in vivo

Translational Lung Cancer Research 2021cited by 36position: middledoi

Elucidating the Role of Serum tRF-31-U5YKFN8DYDZDD as a Novel Diagnostic Biomarker in Gastric Cancer (GC)

Frontiers in Oncology 2021cited by 35position: middledoi

MicroRNA‑195 suppresses cell proliferation, migration and invasion in epithelial ovarian carcinoma via inhibition of the CDC42/CCND1 pathway

International Journal of Molecular Medicine 2020cited by 15position: middledoi

Plasma thymidylate synthase and dihydrofolate reductase mRNA levels as potential predictive biomarkers of pemetrexed sensitivity in patients with advanced non-small cell lung cancer

Journal of Thoracic Disease 2020cited by 4position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Looking for a research collaborator?

Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.

Find collaborators in Cardiology and Cardiovascular Medicine · Complementary and alternative medicine →